Advertisement

Topics

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

2016-10-02 23:07:41 | BioPortfolio

Published on BioPortfolio: 2016-10-02T23:07:41-0400

Clinical Trials [992 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Rifaximin With Xifaxan 200mg in Traveler's Diarrhea

The primary objective is to demonstrate rifaximin 200-mg tablets (test) and Xifaxan® 200 mg tablets (reference ) are clinically bioequivalent with respect to the clinical cure rates when ...

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea

Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide ...

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved ...

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg ...

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting. An ...

PubMed Articles [1121 Associated PubMed Articles listed on BioPortfolio]

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.

Rifaximin, a non-systemic antibiotic, is efficacious for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Given the emerging association between the gut microbiota and IBS, thi...

Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot.

The pathogenesis of nonalcoholic fatty liver disease (NAFLD) may include increased insulin resistance, upregulation of proinflammatory cytokines, lipopolysaccharide, and BMI. Rifaximin is a minimally ...

Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.

Rifaximin-α 550 mg twice daily plus lactulose has demonstrated efficacy in reducing recurrence of episodes of overt HE (OHE) and the risk of HE-related hospitalisations compared with lactulose alon...

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.

Macrophages play a significant role in chronic liver disease as reflected by elevated soluble (s)CD163 and mannose receptor (sMR) levels and associated with liver disease severity and prognosis. Extra...

Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.

Rifaximin is a poorly absorbable antibiotic with a broad-spectrum activity against both Gram-negative and -positive bacteria. It is active in the small intestine due to its high bile solubility, where...

Medical and Biotech [MESH] Definitions

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

Works consisting of publications for travelers that give information about a city, region, or country, or similar handbooks about buildings, museums, etc. (The ALA Glossary of Library and Information Science, 1983)

Products in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. (FDA Backgrounder, June 15, 1993, p2)

Finely powdered native hydrous magnesium silicate. It is used as a dusting powder, either alone or with starch or boric acid, for medicinal and toilet preparations. It is also an excipient and filler for pills, tablets, and for dusting tablet molds. (From Merck Index, 11th ed)

More From BioPortfolio on "A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea."

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial